🇺🇸 induction chemotherapy in United States
9 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 9
Most-reported reactions
- Acute Myeloid Leukaemia — 2 reports (22.22%)
- Acute Graft Versus Host Disease In Intestine — 1 report (11.11%)
- Clostridial Infection — 1 report (11.11%)
- Disease Recurrence — 1 report (11.11%)
- Leukaemia Recurrent — 1 report (11.11%)
- Myelodysplastic Syndrome Transformation — 1 report (11.11%)
- Pneumonia — 1 report (11.11%)
- Relapsing-Remitting Multiple Sclerosis — 1 report (11.11%)
Other Oncology approved in United States
Frequently asked questions
Is induction chemotherapy approved in United States?
induction chemotherapy does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for induction chemotherapy in United States?
Zhejiang Cancer Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.